SARS-CoV 2 Pneumonia
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Long Term Effects of Awake Prone Positioning in COVID-19 ICU Patients
Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia
Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).
Effect of Prone Positionning in Non Intubated Patients
Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests
Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia